Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein
View Patent ↗The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
1. A recombinant or synthetic polypeptide comprising an amino acid sequence that has at least 95 percent amino acid sequence identity to the full-length sequence set forth in SEQ ID NO:239.
2. The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one flavivirus.
3. The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one dengue virus.
4. The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide induces an immune response in a mammal against dengue viruses of multiple serotypes.
5. The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide induces an immune response in a mammal against at least one dengue virus of at least one serotype selected from the group of dengue-1, dengue-2, dengue-3, and dengue-4 that is about equal to or greater than an immune response induced in the mammal against the at least one dengue virus of the at least one serotype by a dengue virus antigen selected from the group of SEQ ID NOS:227-230.
6. The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide comprises the full-length amino acid sequence set forth in SEQ ID NO:239.
7. The recombinant or synthetic polypeptide of claim 1 , wherein the recombinant or synthetic polypeptide induces production of antibodies capable of binding to a first dengue virus of a first serotype and a second dengue virus of a second serotype, wherein the first serotype is different from the second serotype.
8. A composition comprising at least one recombinant or synthetic polypeptide and an excipient or carrier, wherein said polypeptide comprises an amino acid sequence that has at least 95 percent amino acid sequence identity to the full-length sequence set forth in SEQ ID NO:239.
9. A virus-like particle comprising at least one polypeptide, wherein said polypeptide comprises an amino acid sequence that has at least 95 percent amino acid sequence identity to the full-length sequence set forth in SEQ ID NO:239.
10. A method of producing antibodies against at least one dengue virus of at least one serotype comprising administering to a subject at least one recombinant or synthetic polypeptide in an amount sufficient to induce antibody production, wherein said polypeptide comprises an amino acid sequence that has at least 95 percent amino acid sequence identity to the full-length sequence set forth in SEQ ID NO:239.
11. The method of claim 10 , wherein a population of neutralizing antibodies against at least one dengue virus selected of at least one serotype selected from the group of dengue-1, dengue-2, dengue-3, and dengue-4 is induced.
12. A recombinant or synthetic polypeptide comprising an amino acid sequence that has at least 95 percent amino acid sequence identity to the full-length amino acid sequence set forth in SEQ ID NO:239, wherein the amino acid sequence of said polypeptide does not include the first 16 amino acid residues of SEQ ID NO:239, and wherein the recombinant or synthetic polypeptide induces an immune response in a subject against at least one dengue virus.